Generic Name and Formulations:
Trivalent, inactivated, adjuvanted (MF59C.1) influenza vaccine (virus types A and B); contains a total of at least 45mcg of hemagglutinin per 0.5mL dose; formulation changes annually; susp for IM inj; may contain trace amounts of neomycin, kanamycin, barium, egg proteins, formaldehyde; preservative-free.
Indications for FLUAD:
Influenza immunization for patients ≥65yrs of age.
<65yrs: not established. ≥65yrs: 0.5mL IM inj once in the deltoid; 1 dose per year.
Allergy to egg protein. Life-threatening reaction to any previous flu vaccine.
Use current formulation only. Have appropriate medical treatment and supervision readily available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Latex allergy. Pregnancy (Cat.B).
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants (eg, corticosteroids): may get suboptimal response.
Local reactions (eg, pain, tenderness), myalgia, headache, fatigue; syncope.
Single-dose prefilled syringe (0.5mL)—1, 10 (without needles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations